# Merrimack Pharmaceuticals clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Merrimack Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Merrimack Pharmaceuticals: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/merrimack-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 10, 2017 | NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | Merrimack Pharmaceuticals | Phase 1 | Unknown | Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer... | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03076372) |
| May 27, 2016 | NCT02785068 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Merrimack Pharmaceuticals | Phase 1/2 | Withdrawn | Colorectal Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02785068) |
| September 2, 2015 | NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Merrimack Pharmaceuticals | Phase 1 | Terminated | Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02538627) |
| March 26, 2015 | NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | Merrimack Pharmaceuticals | Phase 2 | Completed | Pancreatic Cancer | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02399137) |
| August 11, 2014 | NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer... | Merrimack Pharmaceuticals | Phase 2/3 | Terminated | Breast Cancer, HER2 Positive Breast Cancer | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02213744) |
| January 24, 2013 | NCT01774851 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE)... | Merrimack Pharmaceuticals | Phase 2 | Terminated | HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01774851) |
| November 26, 2012 | NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | Merrimack Pharmaceuticals | Phase 1 | Completed | Hepatocellular Carcinoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01733004) |
| January 30, 2012 | NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Merrimack Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple... | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01520389) |
| December 19, 2011 | NCT01494506 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer | Merrimack Pharmaceuticals | Phase 3 | Completed | Metastatic Pancreatic Cancer | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01494506) |
| October 13, 2011 | NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | Merrimack Pharmaceuticals | Phase 1 | Completed | Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01451632) |
| October 6, 2011 | NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | Merrimack Pharmaceuticals | Phase 2 | Completed | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01447706) |
| October 6, 2011 | NCT01447225 | Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors | Merrimack Pharmaceuticals | Phase 1 | Completed | Solid Tumors | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01447225) |
| August 22, 2011 | NCT01421472 | A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | Merrimack Pharmaceuticals | Phase 2 | Completed | ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01421472) |
| February 25, 2011 | NCT01304797 | Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer | Merrimack Pharmaceuticals | Phase 1 | Unknown | Breast Cancer | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01304797) |
| February 25, 2011 | NCT01304784 | A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer | Merrimack Pharmaceuticals | Phase 1 | Completed | HER-2 Gene Amplification | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01304784) |
| September 27, 2010 | NCT01209195 | A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers | Merrimack Pharmaceuticals | Phase 1 | Completed | Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or... | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01209195) |
| June 25, 2010 | NCT01151046 | Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone... | Merrimack Pharmaceuticals | Phase 2 | Completed | Her2 Negative Breast Cancer Patients | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01151046) |
| April 1, 2010 | NCT01097460 | MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer | Merrimack Pharmaceuticals | Phase 1 | Completed | Breast Neoplasms | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01097460) |
| October 14, 2009 | NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | Merrimack Pharmaceuticals | Phase 1/2 | Completed | Carcinoma, Non-Small-Cell Lung | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00994123) |
| June 3, 2009 | NCT00911898 | A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers | Merrimack Pharmaceuticals | Phase 1 | Completed | Her2 Amplified Solid Tumors, Metastatic Breast Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00911898) |
| August 14, 2008 | NCT00734305 | Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Merrimack Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumors | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00734305) |
| April 9, 2007 | NCT00458146 | A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis | Merrimack Pharmaceuticals | Phase 2 | Completed | Rheumatoid Arthritis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00458146) |
| March 8, 2007 | NCT00444743 | Phase 2 Study of MM-093 to Treat Patients With Uveitis | Merrimack Pharmaceuticals | Phase 2 | Completed | Uveitis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00444743) |
| September 7, 2005 | NCT00147329 | Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis | Merrimack Pharmaceuticals | Phase 2 | Completed | Psoriasis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00147329) |
| March 21, 2005 | NCT00105976 | Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX) | Merrimack Pharmaceuticals | Phase 2 | Completed | Rheumatoid Arthritis | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00105976) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 3 |
| Unknown | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 7 |
| Breast Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Neoplasm Metastasis | 4 |
| Colorectal Neoplasms | 4 |
| Ovarian Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Stomach Neoplasms | 2 |
| Lethal Congenital Contracture Syndrome 2 | 2 |
| Arthritis, Rheumatoid | 2 |
| Pancreatic Neoplasms | 2 |
| Fallopian Tube Neoplasms | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Endometrial Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Esophageal Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Insulin-Like Growth Factor I, Resistance To | 1 |
| Lung Neoplasms | 1 |
| Psoriasis | 1 |
| Fibromatosis, Gingival, 2 | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Recurrence | 1 |
| Carcinoma, Transitional Cell | 1 |
| Small Cell Lung Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Radiology practices in the United States](https://specstream.ai/data/businesses/radiology-practices/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Music schools in the United States](https://specstream.ai/data/businesses/music-schools/united-states)
- [Legal services firms in the United States](https://specstream.ai/data/businesses/legal-services-firms/united-states)
